Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a report published on Saturday morning.

Several other analysts have also issued reports on the company. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Piper Sandler reissued a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Needham & Company LLC cut their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $29.47 on Friday. The company has a market cap of $955.83 million, a PE ratio of 23.77 and a beta of 0.73. The firm has a 50-day moving average of $34.78 and a 200-day moving average of $37.07. Collegium Pharmaceutical has a one year low of $28.01 and a one year high of $50.79. The company has a debt-to-equity ratio of 3.50, a current ratio of 1.14 and a quick ratio of 1.62.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. During the same period in the prior year, the firm earned $1.68 EPS. Collegium Pharmaceutical’s quarterly revenue was up 6.3% compared to the same quarter last year. As a group, equities analysts forecast that Collegium Pharmaceutical will post 6.76 earnings per share for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in COLL. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd grew its holdings in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in Collegium Pharmaceutical during the 4th quarter worth $61,000. PNC Financial Services Group Inc. increased its position in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 418 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 318 shares in the last quarter.

Key Headlines Impacting Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Second-quarter adjusted EPS was $1.92, above analyst expectations of approximately $1.72, while revenue increased 6.3% year over year to $199.9 million. Adjusted EBITDA rose 8% to $113.8 million and operating cash flow was $71.3 million. Collegium Pharmaceutical Q2 Earnings Beat
• Positive Sentiment: The ADHD portfolio showed momentum: JORNAY PM revenue climbed 41% to $46.1 million, and the completed AZSTARYS acquisition contributed $12.9 million in partial-quarter revenue. Collegium raised its full-year AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million, potentially supporting longer-term growth. Collegium Q2 2026 Results
• Neutral Sentiment: Piper Sandler reaffirmed its “neutral” rating but lowered its price target to $43 from $45. Needham retained a “buy” rating while cutting its target to $46 from $56, reflecting continued upside but greater near-term caution. Analyst Price Target Updates
• Negative Sentiment: Collegium reduced full-year product-revenue guidance to $825 million-$855 million from $865 million-$895 million and lowered adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. The company cited lower pricing and weaker-than-expected authorized-generic Nucynta revenue.
• Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta revenue fell 24% and Xtampza ER revenue dropped 14%. GAAP results also shifted to a $15.1 million net loss from $12.0 million of net income, while operating expenses increased 45%, adding pressure to profitability. Collegium Sales and Guidance Report

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.